Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of candida strains

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2655-2659

  Castanheira, Mariana ^a   Woosley, Leah N ^a   Diekema, Daniel J ^b   Messer, Shawn A ^a,b   Jones, Ronald N ^a   Pfaller, Michael A ^b  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; MICAFUNGIN;

AMINO ACID SUBSTITUTION; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; FKS1 GENE; FUNGAL GENE; FUNGAL STRAIN; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA GUILLIERMONDII; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIFUNGAL AGENTS; BASE SEQUENCE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; DNA, FUNGAL; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGAL PROTEINS; GENES, FUNGAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; SEQUENCE HOMOLOGY, AMINO ACID; SPECIES SPECIFICITY;

EID: 77952648499     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01711-09     Document Type: Article

References (17)

1. Baixench, M. T., N. Aoun, M. Desnos-Ollivier, D. Garcia-Hermoso, S. Bretagne, S. Ramires, C. Piketty, and E. Dannaoui. 2007. Acquired resistance to echinocandins in Candida albicans: case report and review. J. Antimicrob. Chemother. 59:1076-1083.
2. Clinical and Laboratory Standards Institute. 2008. M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts. Third edition. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Clinical and Laboratory Standards Institute. 2008. M27-S3. Reference method for broth dilution antifungal susceptibility testing of yeasts. 3rd informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Desnos-Ollivier, M., S. Bretagne, D. Raoux, D. Hoinard, F. Dromer, and E. Dannaoui. 2008. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob. Agents Chemother. 52:3092-3098.
5. Gafter-Gvili, A., L. Vidal, E. Goldberg, L. Leibovici, and M. Paul. 2008. Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin. Proc. 83:1011-1021.
6. Garcia-Effron, G., S. K. Katiyar, S. Park, T. D. Edlind, and D. S. Perlin. 2008. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 52:2305-2312.
7. Garcia-Effron, G., S. Park, and D. S. Perlin. 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother. 53:112-122.
8. Katiyar, S., M. Pfaller, and T. Edlind. 2006. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 50:2892-2894.
9. Kett, D. H., and G. F. Cubillos. 2008. Anidulafungin in the treatment of patients with invasive candidiasis. Int. J. Antimicrob. Agents 32(Suppl. 2): S99-S102.
10. Leaw, S. N., H. C. Chang, H. F. Sun, R. Barton, J. P. Bouchara, and T. C. Chang. 2006. Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions. J. Clin. Microbiol. 44: 693-699.
11. Messer, S. A., G. J. Moet, J. T. Kirby, and R. N. Jones. 2009. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J. Clin. Microbiol. 47:1942-1946.
12. Perlin, D. S. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130.
13. Pfaller, M. A., L. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S. Tendolkar, R. N. Jones, and D. Diekema. 2010. Wild-type MIC distributions and epidemiological cutoff values (ECVs) for the echinocandins and Candida spp. J. Clin. Microbiol. 48:52-56.
14. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2005. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J. Clin. Microbiol. 43:5425-5427.
15. Thompson, G. R., III, N. P. Wiederhold, A. C. Vallor, N. C. Villareal, J. S. Lewis, Jr., and T. F. Patterson. 2008. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob. Agents Chemother. 52:3783-3785.
16. Turnidge, J., G. Kahlmeter, and G. Kronvall. 2006. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin. Microbiol. Infect. 12:418-425.
17. Wiederhold, N. P., J. L. Grabinski, G. Garcia-Effron, D. S. Perlin, and S. A. Lee. 2008. Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. Antimicrob. Agents Chemother. 52:4145-4148.